[132:12] Andrew Huberman That's a good point
The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomised, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly, CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomised, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2)
Interest in BPC-157 stems from its apparent multi-system activity in preclinical research
An endotoxin-free peptide helps ensure that observed experimental outcomes are attributable to the peptide itself rather than unintended immune or inflammatory responses caused by endotoxin contamination
For milder disease, including nondestructive arthritis, enthesitis, and axial disease, treatment with an NSAID may be sufficient
